These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24636244)

  • 41. Emerging epidemic of drug resistant tuberculosis in vulnerable populations of developing countries.
    Hashmi HJ; Javed H; Jamil N
    Afr Health Sci; 2017 Jun; 17(2):599-602. PubMed ID: 29062361
    [No Abstract]   [Full Text] [Related]  

  • 42. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
    Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Alffenaar JW; Caminero JA; Abdo Arbex M; Alarcon Guizado V; Aleksa A; Dore S; Gaga M; Gualano G; Kunst H; Payen MC; Roby Arias AJ; Skrahina A; Solovic I; Sulis G; Tadolini M; Zumla A; Migliori GB;
    Eur Respir J; 2016 Nov; 48(5):1503-1507. PubMed ID: 27587544
    [No Abstract]   [Full Text] [Related]  

  • 43. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
    Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
    Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
    [No Abstract]   [Full Text] [Related]  

  • 44. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.
    Ramón-García S; Ng C; Anderson H; Chao JD; Zheng X; Pfeifer T; Av-Gay Y; Roberge M; Thompson CJ
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3861-9. PubMed ID: 21576426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 46. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 47. Performance evaluation program for Mycobacterium tuberculosis drug-susceptibility testing process.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1994 Jan; 43(1):17-8. PubMed ID: 8272047
    [No Abstract]   [Full Text] [Related]  

  • 48. High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China.
    Chen L; Li N; Liu M; Zhang J; Zhang H
    J Antimicrob Chemother; 2011 Oct; 66(10):2435-7. PubMed ID: 21795258
    [No Abstract]   [Full Text] [Related]  

  • 49. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Reasons for drug-resistant tuberculosis emergence].
    Tu DH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
    [No Abstract]   [Full Text] [Related]  

  • 51. [Shorter treatment of pulmonary tuberculosis is only acceptable with at least 4 drugs in the initial combination of tuberculostatic agents].
    Veen J
    Ned Tijdschr Geneeskd; 1996 Nov; 140(44):2164-7. PubMed ID: 8984351
    [No Abstract]   [Full Text] [Related]  

  • 52. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.
    Rattan A; Kalia A; Ahmad N
    Emerg Infect Dis; 1998; 4(2):195-209. PubMed ID: 9621190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The problems in the chemotherapy of tuberculosis taking into account new data on its causative organism].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2000; 45(5):3-5. PubMed ID: 10862346
    [No Abstract]   [Full Text] [Related]  

  • 54. Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.
    Mahajan NS; Dhawale SC
    Eur J Med Chem; 2015 Sep; 102():243-8. PubMed ID: 26280920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Terizidone.
    Vora A
    J Assoc Physicians India; 2010 Apr; 58():267-8. PubMed ID: 21046890
    [No Abstract]   [Full Text] [Related]  

  • 56. [Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugs].
    Gómez-Ayerbe C; Vivancos MJ; Moreno S
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():35-8. PubMed ID: 27608311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.
    Zhang Y; Yew WW
    Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bedaquiline (Sirturo) for multidrug-resistant tuberculosis.
    Med Lett Drugs Ther; 2013 Aug; 55(1423):66-8. PubMed ID: 23959388
    [No Abstract]   [Full Text] [Related]  

  • 59. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
    Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan.
    Chien JY; Lai CC; Tan CK; Yu CJ; Hsueh PR
    Clin Infect Dis; 2013 Apr; 56(7):1054-5. PubMed ID: 23175554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.